Featured Insights
-
Exploring Payer Coverage Of Anti-Obesity Medications
4/14/2025
Understanding payer strategies for anti-obesity drugs is crucial. A recent study investigated commercial formulary trends, confirming cost as a major barrier despite positive patient outcomes.
-
Exploring Value-Based Contracting In Rare Diseases
4/14/2025
How are payers using value-based contracts for costly rare disease therapies? Exploratory research sheds light on negotiation frequency, preferred contract types, and internal data management trends.
-
5 Questions On Exploring Healthcare Decision-Maker Sentiments
4/14/2025
Research presented at AMCP 2025 uses natural language processing on decision-maker feedback to predict coverage. Learn about the surprising findings and next steps in this Q&A.
-
Scientific Literature Reviews And AI's Potential For Evidence Synthesis
4/14/2025
Scientific literature reviews are crucial for HEOR decision-making but notoriously slow. Explore how AI can potentially accelerate evidence synthesis while maintaining necessary scientific rigor.
-
Key Takeaways From The ISPE Aseptic Processing Seminar
4/14/2025
How is the pharmaceutical industry increasing aseptic processing safety? An ISPE event showcased innovations like robotics and improved risk management, aligning with recent regulatory guidance.
-
Key Takeaways From PDA Ireland Microbiology Event On Innovation And Technology
4/14/2025
Insights from a PDA Ireland event reveal how innovative technologies like VR and automation are transforming sterile manufacturing, improving efficiency and addressing contamination control strategies.
-
Effective Digital Engagement For Biopharma Companies
3/18/2025
The NASP Podcast explores biopharma digital engagement, emphasizing strategic communication, data analytics, and best practices to enhance healthcare decision-maker engagement across a product’s lifecycle.
-
Rising Sun: The Drug Pricing Environment In Japan Is On The Up
3/18/2025
Japan’s recent pharmaceutical pricing reforms present new opportunities for the industry, fostering innovation while aiming to ensure faster access to treatments.
-
Early Network Mapping To Guide HTA Literature Reviews
3/18/2025
How do we identify the right evidence efficiently? Early network mapping can help manufacturers balance a focused scope with the need to conduct indirect treatment comparisons.
-
How Will Medical Devices Be Affected In The Era Of EU HTA?
3/18/2025
The EU Health Technology Assessment Regulation (HTAR) mandates Joint Clinical Assessments (JCAs) for high-risk medical devices and medicines, guiding manufacturers in clinical study requirements and regulatory compliance.